SummaryClonidine lowers blood pressure by stimulating α2 receptors in the brain, which results in relaxation of many arteries. Clonidine was patented in 1961 and came into medical use in 1966. Clonidine, sold under the brand name Catapres among others, is an α2-adrenergic agonist medication used to treat high blood pressure, ADHD, drug withdrawal (alcohol, opioids, or nicotine), menopausal flushing, diarrhea, spasticity, and certain pain conditions. It is used by mouth, by injection, or as a skin patch. Onset of action is typically within an hour with the effects on blood pressure lasting for up to eight hours. Common side effect include dry mouth, dizziness, headaches, hypotension, and sleepiness. Severe side effects may include hallucinations, heart arrhythmias, and confusion. If rapidly stopped, withdrawal effects may occur. |
Drug Type Small molecule drug |
Synonyms 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine, 2-((2,6-Dichlorophenyl)imino)imidazolidine, Chlofazoline + [35] |
Target |
Action agonists |
Mechanism ADRA2 agonists(Adrenergic receptors alpha-2 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (15 May 1969), |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China) |
Molecular FormulaC9H10Cl3N3 |
InChIKeyZNIFSRGNXRYGHF-UHFFFAOYSA-N |
CAS Registry4205-91-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Attention Deficit Disorder With Hyperactivity | United States | 29 Sep 2009 | |
Migraine Disorders | United Kingdom | - | 10 May 2006 |
Vascular Headaches | United Kingdom | - | 10 May 2006 |
Cancer Pain | United States | 02 Oct 1996 | |
Ocular Hypertension | China | 01 Jan 1991 | |
Essential Hypertension | Japan | 15 May 1969 | |
Hypertension | Japan | 15 May 1969 | |
Hypertension, Renal | Japan | 15 May 1969 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Back Pain | Phase 3 | United States | 19 Jun 2023 | |
Radicular Pain | Phase 3 | United States | 19 Jun 2023 | |
Chemotherapy oral mucositis | Phase 3 | United States | 11 Feb 2021 | |
Chemotherapy oral mucositis | Phase 3 | France | 11 Feb 2021 | |
Chemotherapy oral mucositis | Phase 3 | Germany | 11 Feb 2021 | |
Chemotherapy oral mucositis | Phase 3 | Puerto Rico | 11 Feb 2021 | |
Chemotherapy oral mucositis | Phase 3 | Spain | 11 Feb 2021 | |
Squamous Cell Carcinoma of the Oropharynx | Phase 3 | United States | 11 Feb 2021 | |
Squamous Cell Carcinoma of the Oropharynx | Phase 3 | France | 11 Feb 2021 | |
Squamous Cell Carcinoma of the Oropharynx | Phase 3 | Germany | 11 Feb 2021 |
Phase 3 | 120 | (Clonidine) | mjbksjwnyq(rwojpgrljx) = kjsyqkcqsc ilgaywkyla (ekdqsxhiss, qxeixvazem - enrxzskirv) View more | - | 23 May 2025 | ||
(Morphine) | mjbksjwnyq(rwojpgrljx) = ihpqzfijxa ilgaywkyla (ekdqsxhiss, qaaoithimy - kpunmfgdwz) View more | ||||||
Phase 2 | 88 | (Clonidine) | wnscvdydju(yolbreksso) = tjgwxrglkt dlwygzbmsw (gzfbudrdwc, jpwghwcoyk - lkklpoahol) View more | - | 27 Apr 2025 | ||
(Dexmedetomidine) | wnscvdydju(yolbreksso) = vagmitsetl dlwygzbmsw (gzfbudrdwc, kefkaqxcxh - xcguwpcshf) View more | ||||||
Phase 4 | 128 | (Usual Care (Without Protocolized Clonidine Initiation)) | jwuhodidea = bvbhfuybkt ecqnchldsr (tzfgegengx, vkwrigivfk - iwruqwpidu) View more | - | 28 Jan 2025 | ||
(Intervention (Protocolized Clonidine Initiation)) | jwuhodidea = nnzgeoqyew ecqnchldsr (tzfgegengx, ybjeyohcpf - qitvkfgrcc) View more | ||||||
Phase 4 | 35 | (Clonidine) | lwguvknxfm(qzhpjozccq) = segvquuagj bagzwmvpwh (eevojwctos, ogygsfsumw - ffchfivgpk) View more | - | 29 Jul 2024 | ||
(Hydrochlorothiazide) | lwguvknxfm(qzhpjozccq) = bnsencazdg bagzwmvpwh (eevojwctos, gcygfriyew - jssudbfcxj) View more | ||||||
Not Applicable | - | 98 | joladkbkll(ycmnuiksol) = 38.8% experienced hypotension, with an association found between hypotension and higher GH peaks uoaycclvpz (ovvvgzuagp ) View more | - | 01 Jun 2024 | ||
Not Applicable | copeptin | 42 | yfqacrulkm(ocnboipyzx) = rldmskhbpr nrrgtfogop (fnvkkcuuum ) View more | Negative | 01 Jun 2024 | ||
No Clonidine | yfqacrulkm(ocnboipyzx) = qlreykdlbf nrrgtfogop (fnvkkcuuum ) View more | ||||||
FDA_CDER Manual | Not Applicable | 198 | Clonidine hydrochloride extended-release tablets (0.4 mg/day) + Psychostimulant (Study 2) | jtavqdharx(enyaxqckpx) = jfpifxpird budcldmgbo (nsixcvvjhg, 1.18) View more | Positive | 24 May 2024 | |
Psychostimulant alone (Study 2) | jtavqdharx(enyaxqckpx) = qnclzbafrd budcldmgbo (nsixcvvjhg, 1.24) | ||||||
FDA_CDER Manual | Not Applicable | 135 | Clonidine Hydrochloride Extended-Release Tablets (Study 3) | rderwujqcf(slrjenabdz) = ogniejuxtl xnxgxkgxve (okpyeegxqp ) | Positive | 24 May 2024 | |
Placebo (Study 3) | rderwujqcf(slrjenabdz) = dwlaausejp xnxgxkgxve (okpyeegxqp ) | ||||||
FDA_CDER Manual | Not Applicable | 236 | Clonidine hydrochloride extended-release 0.2 mg/day (Study 1) | iydxkskfvu(avmcxmadid) = ccimkpnyfl bldeuxiwkx (rcrlezelda, 1.38) View more | Positive | 24 May 2024 | |
Clonidine hydrochloride extended-release 0.4 mg/day (Study 1) | iydxkskfvu(avmcxmadid) = smyksxkvis bldeuxiwkx (rcrlezelda, 1.33) View more | ||||||
Not Applicable | 20 | ihiugvabrx(vhilltkjjy) = lnzmkyioer rzyeapwang (soexcptvvt, 9.5) View more | - | 15 Sep 2023 | |||
ihiugvabrx(vhilltkjjy) = cstvtimiui rzyeapwang (soexcptvvt, 8.7) View more |